Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Valentino ConterMaria Grazia ValsecchiGunnar CarioMartin ZimmermannAndishe AttarbaschiJan StaryFelix K NiggliLuciano Dalla PozzaSarah ElitzurDaniela SilvestriFranco LocatelliAnja MörickeGernot EngstlerPetr SmisekNicole BodmerDraga BarbaricShai IzraeliCarmelo RizzariJoachim BoosBarbara BuldiniMassimo ZucchettiArend von StackelbergCristina MatteoThomas LehrnbecherClaudia Lanvers-KaminskyGiovanni CazzanigaBernd GruhnAndrea BiondiMartin SchrappePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Additional PEG-ASNASE in phase IB did not translate into a benefit for decreasing relapse incidence but was associated with higher toxicity. Further improvements with conventional chemotherapy might be difficult in the context of intensive treatment protocols.